Table 9.
Suggested doses of immunogens for rats and hamsters
| Form of antigen | Examples | Primary injections and boosts | Final boosts | ||||
|---|---|---|---|---|---|---|---|
| Possible routesa | Dose | Adjuvant | Possible routesa | Dose | Adjuvant | ||
| Soluble proteins | Enzymes | i.p., s.c. | 10–100 µg | + | i.v. | 10–100 µg | – |
| Carrier proteins conjugated with peptides | |||||||
| Immune complexes | |||||||
| Particulate proteins | Viruses (killed) | i.p., s.c. | 10–100 µg | + | i.v. | 10–100 µg | – |
| Yeast (killed) | |||||||
| Bacteria (killed) | |||||||
| Structural proteins | |||||||
| Insoluble proteins | Bacterially produced from inclusion bodies | ||||||
| Immunopurified proteins bound to beads | i.p., s.c. | 10–100 µg | + | i.p. | 10–100 µg | – | |
| Live cells | Mammalian cells | i.p. | 106–108 cells | +/– | i.v. | 107 cells | – |
| Live tumorigenic cells | Oncogenic mammalian cells | i.p., s.c. | 105–107 cells | +/– | i.v. | 107 cells | – |
| Carbohydrates | Polysaccharides | ||||||
| Glycoproteins | i.p., s.c. | 20–100 µg | +/– | i.v. | 20–100 µg | – | |
| Nucleic acids | Carrier proteins conjugated with nucleic acids | i.p. | 20–100 µg | + | i.v. | 20–100 µg | – |
-
ai.p., intraperitoneal; s.c., subcutaneous; i.v., intravenous.










